Atreca's - BCEL market analysis on 24th January 2021

Transaction Date	Recipient	Shares	Type	Price	Value
14th January 2021	William Hewitt Robinson	2,259	Open or private sale	$15.06	$34,010.83
13th January 2021	William Hewitt Robinson	2,741	Open or private sale	$15.05	$41,238.62
4th January 2021	Bros. Advisors Lp Baker	10,060	Open or private sale	$220.50	$2,218,230.00
4th January 2021	Bros. Advisors Lp Baker	111,094	Open or private sale	$220.50	$24,496,227.00
31st December 2020	Bros. Advisors Lp Baker	343	Grant/award etc.	$0.00
31st December 2020	Bros. Advisors Lp Baker	343	Grant/award etc.	$0.00
17th December 2020	Norman Michael Greenberg	5,000	Exercise of derivative	$4.56	$22,800.00
17th December 2020	Norman Michael Greenberg	5,000	Open or private sale	$16.61	$83,051.00
11th December 2020	Tito Serafini	10,000	Open or private sale	$15.87	$158,735.00
4th December 2020	Bros. Advisors Lp Baker	125,513	Open or private sale	$220.50	$27,675,616.50

Atreca

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 3/10.

Atreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients.

Ticker: BCEL

Sector: Health Technology

Industry: Biotechnology

SEC Central Index Key (CIK): 1532346

Employees: 113

Exchange: NASDAQ

Auditor Opinion:

You must Login to see Language Changes

Disclosure Language changes

Analysis of subtle changes in disclosure language. Red is a sign of more constrained, less positive language changes etc. Green is more positive, less constrained etc.

You must Login to see analysis